In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens

Maren Eggers, Torsten Koburger-Janssen, Markus Eickmann, Juergen Zorn, Maren Eggers, Torsten Koburger-Janssen, Markus Eickmann, Juergen Zorn

Abstract

Introduction: Recent virus epidemics and rising antibiotic resistance highlight the importance of hygiene measures to prevent and control outbreaks. We investigated the in vitro bactericidal and virucidal efficacy of povidone-iodine (PVP-I) 7% gargle/mouthwash at defined dilution against oral and respiratory tract pathogens.

Methods: PVP-I was tested against Klebsiella pneumoniae and Streptococcus pneumoniae according to bactericidal quantitative suspension test EN13727 and against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses (SARS-CoV and MERS-CoV), rotavirus strain Wa and influenza virus A subtype H1N1 according to virucidal quantitative suspension test EN14476. PVP-I 7% gargle/mouthwash was diluted 1:30 with water to a concentration of 0.23% (the recommended concentration for "real-life" use in Japan) and tested at room temperature under clean conditions [0.3 g/l bovine serum albumin (BSA), viruses only] and dirty conditions (3.0 g/l BSA + 3.0 ml/l erythrocytes) as an interfering substance for defined contact times (minimum 15 s). Rotavirus was tested without protein load. A ≥ 5 log10 (99.999%) decrease of bacteria and ≥ 4 log10 (99.99%) reduction in viral titre represented effective bactericidal and virucidal activity, respectively, per European standards.

Results: PVP-I gargle/mouthwash diluted 1:30 (equivalent to a concentration of 0.23% PVP-I) showed effective bactericidal activity against Klebsiella pneumoniae and Streptococcus pneumoniae and rapidly inactivated SARS-CoV, MERS-CoV, influenza virus A (H1N1) and rotavirus after 15 s of exposure.

Conclusion: PVP-I 7% gargle/mouthwash showed rapid bactericidal activity and virucidal efficacy in vitro at a concentration of 0.23% PVP-I and may provide a protective oropharyngeal hygiene measure for individuals at high risk of exposure to oral and respiratory pathogens.

Funding: Mundipharma Research GmbH & Co. KG (MRG).

Keywords: Anti-infective agents; Local; Microbial sensitivity tests; Mouthwashes; Povidone-iodine; Respiratory tract infections.

References

    1. World Health Organization. Antibiotic resistance fact sheet. 2016. . Accessed Mar 2018.
    1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013. . Accessed Mar 2018.
    1. World Health Organization. Resistant pneumococcal infections; the burden of disease and challenges in monitoring and controlling antimicrobial resistance. 2001. . Accessed Mar 2018.
    1. World Health Organization. Influenza (seasonal) fact sheet. 2016. . Accessed Mar 2018.
    1. World Health Organization. Frequently asked questions on Middle East respiratory syndrome coronavirus (MERS-CoV). 2015. . Accessed Mar 2018.
    1. Centers for Disease Control and Prevention. SARS basics fact sheet. 2004. . Accessed Mar 2018.
    1. Berry M, Gamieldien J, Fielding BC. Identification of new respiratory viruses in the new millennium. Viruses. 2015;7:996–1019. doi: 10.3390/v7030996.
    1. Hsieh YH. 2015 Middle East respiratory syndrome coronavirus (MERS-CoV) nosocomial outbreak in South Korea: insights from modeling. PeerJ. 2015;3:e1505. doi: 10.7717/peerj.1505.
    1. World Health Organization. WHO guidelines on hand hygiene in health care. 2009. . Accessed Mar 2018.
    1. Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee. HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51:1–45.
    1. Gralton J, Tovey ER, McLaws ML, Rawlinson WD. Respiratory virus RNA is detectable in airborne and droplet particles. J Med Virol. 2013;85:2151–2159. doi: 10.1002/jmv.23698.
    1. World Health Organization. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). 2003. . Accessed Mar 2018.
    1. World Health Organization. Infection prevention and control during health care for probable or confirmed cases of novel coronavirus (nCoV) infection: interim guidance. 2013. . Accessed Mar 2018.
    1. Kitamura T, Satomura K, Kawamura T, Great Cold Investigators-I et al. Can we prevent influenza-like illnesses by gargling? Intern Med. 2007;46:1623–1624. doi: 10.2169/internalmedicine.46.0104.
    1. Sneader W. Drug discovery: a history. New York: Wiley; 2005. p. 68.
    1. McLure AR, Gordon J. In-vitro evaluation of povidone-iodine and chlorhexidine against methicillin-resistant Staphylococcus aureus. J Hosp Infect. 1992;21:291–299. doi: 10.1016/0195-6701(92)90139-D.
    1. Traoré O, Fayard SF, Laveran H. An in vitro evaluation of the activity of povidone-iodine against nosocomial bacterial strains. J Hosp Infect. 1996;34:217–222. doi: 10.1016/S0195-6701(96)90069-9.
    1. Shimizu M, Okuzumi K, Yoneyama A, et al. In vitro antiseptic susceptibility of clinical isolates from nosocomial infections. Dermatology. 2002;204(Suppl 1):21–27. doi: 10.1159/000057720.
    1. Gorman SP, Scott EM, Hutchinson EP. Effects of aqueous and alcoholic povidone-iodine on spores of Bacillus subtilis. J Appl Bacteriol. 1985;59:99–105. doi: 10.1111/j.1365-2672.1985.tb01780.x.
    1. Rikimaru T, Kondo M, Kondo S, Oizumi K. Bactericidal activities of povidone-iodine against Mycobacterium. Dermatology. 1997;195(Suppl 2):104–106. doi: 10.1159/000246041.
    1. Wutzler P, Sauerbrei A, Klöcking R, Brögmann B, Reimer K. Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine. Antiviral Res. 2002;54:89–97. doi: 10.1016/S0166-3542(01)00213-3.
    1. Kawana R, Kitamura T, Nakagomi O, et al. Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. Dermatology. 1997;195(Suppl 2):29–35. doi: 10.1159/000246027.
    1. Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatology. 2006;212(Suppl 1):119–123. doi: 10.1159/000089211.
    1. Eggers M, Eickmann M, Kowalski K, Zorn J, Reimer K. Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses. BMC Infect Dis. 2015;15:375. doi: 10.1186/s12879-015-1111-9.
    1. Eggers M, Eickmann M, Zorn J. Rapid and effective virucidal activity of povidone-iodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus ankara (MVA) Infect Dis Ther. 2015;4:491–501. doi: 10.1007/s40121-015-0091-9.
    1. Committee for the Japanese Respiratory Society Guidelines in Management of Respiratory Prevention of hospital-acquired pneumonia (strategies for prevention of hospital-acquired infections) Respirology. 2004;9:S48–S50. doi: 10.1111/j.1440-1843.2003.00552.x.
    1. EN 13727:2012 + A2@2015. Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of bactericidal activity in the medical area. Test method and requirements (Phase 2/Step 1). 2015.
    1. EN 14476:2013/FprA1:2015. Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of virucidal activity in the medical area. Test method and requirements (Phase 2/Step 1). 2015.
    1. ISODINE® Gargle P [package insert]. Shiongi Healthcare Co., Ltd, 2017.
    1. Spearman C. The method of ‘right and wrong cases’ (‘constant stimuli’) without Gauss’s formulae. Br J Psychol. 1908;2:227–242.
    1. Kärber G. Beitrag zur Kollektiven Behandlung Pharmakologischer Reihenversuche [article in German] Arch Exp Path Pharm. 1931;162:480–487. doi: 10.1007/BF01863914.
    1. Yoneyama A, Shimizu M, Tabata M, Yashiro J, Takata T, Hikida M. In vitro short-time killing activity of povidone-iodine (Isodine Gargle) in the presence of oral organic matter. Dermatology. 2006;212(Suppl 1):103–108. doi: 10.1159/000089207.
    1. Shiraishi T, Nakagawa Y. Evaluation of the bactericidal activity of povidone-iodine and commercially available gargle preparations. Dermatology. 2002;204(Suppl 1):37–41. doi: 10.1159/000057723.
    1. Ito H, Ito T, Hikida M, et al. Outbreak of highly pathogenic avian influenza in Japan and ant-influenza virus activity of povidone-iodine products. Dermatology. 2006;212(Suppl 1):115–118. doi: 10.1159/000089210.
    1. Sriwilaijaroen N, Wilairat P, Hiramatsu H, et al. Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities. Virol J. 2009;6:124. doi: 10.1186/1743-422X-6-124.
    1. Steinmann J, Paulmann D, Becker B, Bischoff B, Steinmann E, Steinmann J. Comparison of virucidal activity of alcohol-based hand sanitizers versus antimicrobial hand soaps in vitro and in vivo. J Hosp Infect. 2012;82:277–280. doi: 10.1016/j.jhin.2012.08.005.
    1. Sauerbrei A, Wutzler P. Virucidal efficacy of povidone-iodine-containing disinfectants. Lett Appl Microbiol. 2010;51:158–163.
    1. Gottardi W. Iodine and iodine compounds. In: Block SS, editor. Disinfection, sterilization and preservation. Philadelphia: Lea & Febiger; 1991. pp. 152–166.
    1. Kanagalingam J, Feliciano R, Hah JH, Labib H, Le TA, Lin JC. Practical use of povidone-iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections. Int J Clin Pract. 2015;69(11):1247–1256. doi: 10.1111/ijcp.12707.
    1. Japan Ministry of Health, Labour and Welfare. Pandemic influenza preparedness action plan of the Japanese Government. 2007. . Accessed Mar 2018.
    1. Nagatake T, Ahmed K, Oishi K. Prevention of respiratory infections by povidone-iodine gargle. Dermatology. 2002;204(Suppl 1):32–36. doi: 10.1159/000057722.
    1. Satomura K, Kitamure T, Kawamura T, Great Cold Investigators-I et al. Prevention of upper respiratory tract infections by gargling: a randomized trial. Am J Prev Med. 2005;29:302–307. doi: 10.1016/j.amepre.2005.06.013.
    1. Okuda M, Kaneko Y, Ichinohe T, Ishihara K, Okuda K. Reduction of potential respiratory pathogens by oral hygienic treatment in patients undergoing endotracheal anesthesia. J Anesth. 2003;17:84–91. doi: 10.1007/s005400300022.
    1. Madan PD, Sequeira PS, Shenoy K, Shetty J. The effect of three mouthwashes on radiation-induced oral mucositis in patients with head and neck malignancies: a randomized control trial. J Cancer Res Ther. 2008;4:3–8. doi: 10.4103/0973-1482.39597.
    1. Rahn R, Adamietz IA, Boettcher HD, Schaefer V, Reimer K, Fleischer W. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology. 1997;195(Suppl 2):57–61. doi: 10.1159/000246032.
    1. Lanjri S, Uwingabiye J, Frikh M, et al. In vitro evaluation of the susceptibility of Acinetobacter baumannii isolates to antiseptics and disinfectants: comparison between clinical and environmental isolates. Antimicrob Resist Infect Control. 2017;6:36. doi: 10.1186/s13756-017-0195-y.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe